Last reviewed · How we verify
NCT04611880
Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
Phase 2 trial testing Crizanlizumab in RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy in 20 participants. Participants enrolled and being followed up; not accepting new ones.
2 April 2025
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 25 January 2021 |
| Primary completion | 2 April 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Crizanlizumab (CRIZANLIZUMAB) — full drug profile →
Conditions studied
- RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy — all drugs for RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy →
Sponsor
Washington University School of Medicine
Who can join
Adults 25 to 75, any sex, with RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 2 trial that will test the efficacy and safety of crizanlizumab for the treatment of retinal vasculopathy with cerebral leukoencephalopathy (RVCL), a very rare and uniformly fatal genetic condition that affects the microvasculature, especially of the brain and eye. There currently is no treatment for RVCL. A maximum of 20 patients will be enrolled.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
P- and E- selectin in venous thrombosis and non-venous pathologies.
Purdy M, Obi A, Myers D, Wakefield T. · · 2022 · cited 60× · PMID 35243742 · DOI 10.1111/jth.15689 -
Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations (RVCL-S): An update on basic science and clinical perspectives.
Wilms AE, de Boer I, Terwindt GM. · · 2022 · cited 15× · PMID 36324396 · DOI 10.1016/j.cccb.2022.100046 -
Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation.
Escopy S, Chaikof EL. · · 2024 · cited 8× · PMID 40766814 · DOI 10.1016/j.bvth.2024.100015 -
Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study.
Wang WX, Spiegelman D, Rao PK, Rhee RL, et al · · 2024 · cited 6× · PMID 38950286 · DOI 10.1172/jci180916 -
Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations: Critical Role of Retina Specialists.
Houghton OM, Carter J, Dhamija R. · · 2023 · cited 2× · PMID 37006667 · DOI 10.1177/24741264221129095 -
Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases.
Zhong X, D'Antona AM, Rouse JC. · · 2024 · PMID 39596031 · DOI 10.3390/ijms252211962
Verify or expand the search:
- PubMed search for NCT04611880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Crizanlizumab
Trials testing the same drug.
- NCT06439082 — A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult · Phase 3 · recruiting
- NCT05469828 — Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia · Phase 1, PHASE2 · not yet recruiting
- NCT05334576 — Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA · NA · unknown
- NCT05020873 — Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and · terminated
- NCT05494541 — Characteristics of Patients With Sickle Cell Disease · completed
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04611880 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04611880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing